The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; Clovis Oncology; GlaxoSmithKline; MSD; Netcancer; Pfizer
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Eisai; Gilead Sciences; GlaxoSmithKline; MSD; Novartis; Pfizer; Sanofi
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; MSD; Netcancer; Pfizer
Research Funding - MSD; Novartis; Pfizer; Seagen
Travel, Accommodations, Expenses - Gilead Sciences; MSD; Pfizer
Immune features of ovarian tumors with a good response to neo-adjuvant chemotherapy in combination with an anti-PD-L1 alone or with an anti-CTLA4: Data from the randomized IneOV trial (a GINECO study).
 
Alexandra Leary
Honoraria - Medscape
Consulting or Advisory Role - Apmonia Therapeutics (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Merck Serono (Inst); MSD (Inst); PEGASCY; Tesaro (Inst); zentalis
Research Funding - Inivata (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Tesaro
 
Laure Chardin
Research Funding - AstraZeneca
 
Catherine Genestie
No Relationships to Disclose
 
Alain Lortholary
Honoraria - AstraZeneca; clovis oncology; MSD; Novartis; Roche; Tesaro/GSK; Tesaro/GSK
 
Jerome Alexandre
Honoraria - AstraZeneca; Clovis Oncology; Eisai Europe; GlaxoSmithKline; Janssen Oncology; MSD Oncology; MSD Oncology; Novartis; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Eisaï; GlaxoSmithKline; Janssen Oncology; MSD Oncology
Research Funding - GlaxoSmithKline (Inst); Janssen (Inst); MSD Oncology (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Eisai Europe; Janssen; Novartis
 
Thibault De La Motte Rouge
No Relationships to Disclose
 
Veronique D'hondt
Travel, Accommodations, Expenses - GlaxoSmithKline; Lilly
 
Anne Floquet
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline; MSD Oncology; Roche; Tesaro
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; GlaxoSmithKline; MSD Oncology; Roche; Tesaro
 
Aude-Marie Savoye
No Relationships to Disclose
 
Nicolas Delanoy
Honoraria - AstraZeneca; Clovis Oncology; GlaxoSmithKline; MSD Oncology
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Céline Gavoille
No Relationships to Disclose
 
Benoit You
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Clovis Oncology; Daiichi Sankyo Europe GmbH; ECS PROGASTRIN; GlaxoSmithKline; Immunomedics; LEK; MSD Oncology; Myriad Genetics; Novartis; Roche/Genentech; Seagen; TESARO
Research Funding - Clovis Oncology (Inst); Merck Serono (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; BMS; MSD Oncology; Roche/Genentech; SEAGEN
 
Julien Grenier
Travel, Accommodations, Expenses - AstraZeneca; Eisai Europe
 
Elisa Yaniz-Galende
No Relationships to Disclose